Oral salmon calcitonin - pharmacology in osteoporosis
Oral salmon calcitonin - pharmacology in osteoporosis
复制标题
DOI：
10.1517/14712598.2010.526104
复制
发表时间：
2010-11-01
影响因子：
4.6
通讯作者：
Karsdal, Morten Asser
中科院分区：
文献类型：
--
作者：
Henriksen, Kim;Bay-Jensen, Anne-Christine;Karsdal, Morten Asser
该领域的重要性：骨质疏松症是一种数十年发展的缓慢进行性疾病，需要长期干预。这突出了安全干预可能性的必要性，这些可能性在治疗后具有持续的有益效果。本综述涵盖的领域：从1960年至今，Pubmed上出现的关于鲑鱼降钙素的文章，重点是一种新开发的口服制剂，与鼻制剂相比，其暴露量和疗效增加。后半部分侧重于长期现象，如骨质量和分辨率的影响。最后一部分讨论了鲑鱼降钙素的潜在额外好处。读者将获得什么：深入了解口服配方肽的临床发展，以及详细了解为什么这种方法可以恢复鲑鱼降钙素作为骨质疏松症的治疗方法。要点：根据I期和II期临床试验数据，与鼻用制剂相比，鲑鱼降钙素口服制剂对骨骼有额外的益处和更高的疗效。因此，人们对正在进行的III期压裂试验的结果充满了兴趣。
Importance of the field: Osteoporosis is a slow progressive disease with develops over decades, and where intervention is needed for an extended number of years. This highlights the need for safe intervention possibilities, which have sustained beneficial effects post-treatment.Areas covered in this review: Articles on salmon calcitonin appearing on Pubmed from 1960 until today, with focus on a newly developed oral formulation showing increased exposure and efficacy compared with nasal formulation is reviewed. The second half focuses on long-term phenomena, such as bone quality and resolution effects. The final part discusses potential additional benefits of salmon calcitonin.What the reader will gain: Insight into the clinical development of an orally formulated peptide, as well as a detailed understanding of why this approach could revive salmon calcitonin as a treatment for osteoporosis.Take home message: The oral formulation of salmon calcitonin provides additional benefits and increased efficacy on bone based on Phase I and II clinical trials data, as compared with the nasal formulation. Hence, the results on the ongoing Phase III fracture trial are awaited with great interest.